Background: Insulin resistance (IR), which is a state of deficient response to normal insulin levels, is associated with metabolic abnormalities of dyslipidemia, glucose intolerance, obesity, and hypertension, parameters which define metabolic syndrome (MS). Markers of IR could be useful tools to predict MS. Aim: This study aims to evaluate the performance of surrogate markers of IR in predicting MS in nondiabetic adult Nigerians. Settings and Design: This cross-sectional, analytical study was conducted in Lagos, Nigeria. Subjects and Methods: One hundred and forty-one apparently healthy adult Nigerians aged between 40 and 80 years were consecutively recruited. MS was defined according to the harmonized MS criteria. Data were collected using a questionnaire, and fasting blood samples were collected for analysis. Statistical Analysis: The data were analyzed using the IBM SPSS statistical package. Statistical significance was set at P < 0.05.
Introduction
Insulin resistance (IR) is defined as decreased response to normal concentrations of circulating insulin with decreased insulin-stimulated peripheral glucose utilization and failure to suppress free fatty acid release from adipose tissue and hepatic glucose production. [1] IR, therefore, triggers a cascade of metabolic abnormalities including cardiometabolic risk factors of dyslipidemia (high triglyceride and low high-density lipoprotein [HDL]-cholesterol), hypertension, raised fasting glucose, and central obesity. The clustering of these risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together more often than by chance alone, is known as metabolic syndrome (MS). The presence of MS signifies increased risk for atherosclerotic cardiovascular disease (CVD). [2] IR increases with age; [3] increasing age is associated with decreased glucose tolerance as manifested by a reduction in glucose-mediated B-cell insulin release and deficient insulin-mediated skeletal muscle glucose disposal, creating a state of IR. [4, 5] IR plays a pivotal role in the pathogenesis of age-related diseases of CVD, MS, and type 2 diabetes, and the assessment of IR status may have a role in risk stratification and inform treatment options.
Standard measurements of IR include the euglycemic hyperinsulinemic clamp, the hyperglycemic clamp, and the insulin suppression test. [6, 7] These in vivo techniques which are direct measures of insulin sensitivity are technically demanding and invasive, requiring insulin infusion and repeated blood sampling and the continuous adjustment of glucose infusions. [8] These methods are impractical in large epidemiological studies and in clinical settings, creating a need for the use of surrogate markers. Surrogate markers of IR include the Homeostatic Model for Insulin Assessment (HOMA), which provided equations for estimating IR (HOMA-IR) and beta cell function (HOMA-B) from simultaneous fasting measures of insulin and glucose levels, [8] by mathematical modeling of the normal physiological dynamics of insulin and glucose. The Quantitative Insulin Sensitivity Check Index (QUICKI) derived from logarithmically transformed fasting plasma glucose and insulin levels has proven to be a first-rate index of IR compared with the clamp methods. [9] The fasting glucose-insulin ratio (FGIR) is another surrogate marker which has been employed in a number of studies as an index of IR and insulin sensitivity. [10, 11] These markers have been validated against standard measures of insulin sensitivity, [10] but their performance in certain clinical states such as MS has not been evaluated in adult Nigerians.
Subjects and Methods
This was a cross-sectional, analytical study of 141 apparently healthy adult male and female Nigerians aged between 40 and 80 years who were recruited from an urban population in Lagos, Nigeria. Announcement for enrollment was made, and individuals who responded to the call, met the inclusion criteria, and gave written informed consent were consecutively recruited into the study. The Institutional Review Board of the College of Medicine, University of Lagos, approved the study protocol.
MS is defined as a combination of at least three of the following five criteria: abdominal circumference ≥102 cm in males or ≥88 cm in females, HDL-cholesterol <1.03 mmol/L (<40 mg/dL) in males or <1.3 mmol/L (<50 mg/dL) in females, triglycerides ≥1.7 mmol/L (≥150 mg/dL), blood pressure ≥130/85 mmHg or the patient receiving hypotensive treatment, and fasting glycemia >6.1 mmol/L (>110 mg/dL). [12] Individuals who were not ambulant, pregnant women, and institutionalized individuals were excluded from the study. Individuals with diabetes were also excluded from the study.
The eligible study participants were counseled on the objectives of the study and the study protocol. The study was conducted according to the guidelines laid down in the Declaration of Helsinki, and the Institutional Review Board of the University of Lagos approved the protocol. Each participant completed an interviewer-administered, anonymous, standardized questionnaire. The participants then underwent anthropometric measurements and blood pressure measurements. Abdominal obesity was determined by measurement of the waist circumference. The measurement was taken at the end of several consecutive natural breaths, at a level parallel to the floor, and at the midpoint between the top of the iliac crest and the lower margin of the last palpable rib in the mid-axillary line. [13] The hip circumference was measured at a level parallel to the floor, at the largest circumference of the buttocks. [13] General obesity was determined by the body mass index. [14] Weight was measured to the nearest 0.1 kg and height to the nearest 0.1 m.
Blood pressure was determined using the Accoson's mercury sphygmomanometer (cuff size 15 cm × 43 cm). The participants were seated and rested for 5 min before measurement. Systolic blood pressure was taken at the first Korotkoff sound and diastolic blood pressure at the fifth Korotkoff sound. [15] The study participants reported on the morning of the study after an overnight (10-12 h) fast. Venous blood was collected for fasting glucose, lipid profile, and insulin measurements. study participants were evaluated by age, gender, ethnicity, educational level, and religion. All the variables were evenly distributed across groups, showing no statistically significant differences.
Majority of the study participants were aged between 40 and 60 years old, representing 68.2% with MS and 79.1% without MS. More females than males had MS, 63.2% compared to 51.7%, though the difference was not statistically significant. The major ethnic groups that participated in the study were Yoruba and Igbo and both were evenly distributed in the groups, with and without MS. There was no statistically significant difference in the levels of education and religious affiliation between the groups with and without MS. Table 2 shows the reference intervals for the markers of IR, FGIR, HOMA-IR, HOMA-B, and QUICKI in adult Nigerians aged 40-80 years of age.
The reference interval for the study population defines the 2.5% and 97.5% boundaries that define the normal limits for markers of IR in an apparently healthy (with and without MS) adult Nigerian population aged 40-80 years. IR was assessed using HOMA-IR, HOMA-B, QUICKI index, and FGIR and calculated thus: HOMA-IR = fasting insulin (µIU/mL) × fasting glucose (mmol/L)/22.5.
[8] HOMA-%B = fasting insulin (µIU/ml) × 100/fasting glucose (mmol/L). [16] QUICKI = 1/[log (insulin µU/mL) + log (glucose mg/dL) [17] and FGIR = fasting glucose (mmol/L) × fasting insulin (µIU/ml). [18] Statistical analysis The data were analyzed using IBM Statistical Software for Social Sciences (SPSS Inc., Chicago, IL) version 20.0.. The Chi-squared test, independent Student's t-test, Spearman's correlation, and receiver operating characteristic (ROC) curve were employed for the analysis. Statistical significance was set at P < 0.05.
Results
One hundred and forty-one apparently healthy adult Nigerians participated in this study. Nearly 15.6% of participants had MS, whereas 84.4% did not have MS. Almost 36.8% of the participants were male, whereas 63.2% were female. The age range was 40-80 years, with a mean of 52.29 ± 9.42 years. Table 1 shows the sociodemographic data of the study participants. The sociodemographic characteristics of the Figure 1 shows the performance of markers of IR, i.e., FGIR, HOMA-IR, HOMA-B, and QUICKI, in the study participants in diagnosing MS. Table 4 shows the characteristics of the markers of IR, i.e., FGIR, HOMA-IR, HOMA-B, and QUICKI, with respect to area under the ROC curve (AUC), confidence intervals, sensitivity, and specificity, in diagnosing MS.
At a cutoff value of − 0.966, HOMA-IR had the narrowest AUC, at 100% sensitivity and zero specificity, followed by HOMA-B, with an AUC of 0.589, at a cutoff value of 3.090, a sensitivity of 74%, and a specificity of 40%. FGIR, at a cutoff value of 0.477, had an AUC of 0.611, a sensitivity of 95%, and a specificity of 40%. While QUICKI had the highest AUC of 0.722, at a cutoff value of 0.324 and a sensitivity and specificity of 90% and 40%, respectively. 
Discussion
All parameters taken together, this study returns QUICKI as the best surrogate marker for IR in an adult population of Nigerians with MS. Mean values for QUICKI were significantly lower in individuals with one or more components of MS, moderately but significantly correlated with MS, and had the largest AUC at a sensitivity of 90% albeit at a specificity of 40%.
The gold standard method for measuring IR is the euglycemic hyperinsulinemic clamp. [6] This is a direct method of estimating IR. It is, however, technically demanding and invasive, requiring insulin infusion and repeated blood sampling with continuous adjustment of glucose infusion. [8] The euglycemic hyperinsulinemic clamp method is impractical in large epidemiological studies and in clinical settings, creating a need for the use of surrogate markers.
A recent review of surrogate markers of IR focused on the pros and cons of these markers. [19] HOMA-IR, HOMA-B, FGIR, and QUICKI are surrogate markers derived from fasting steady-state conditions and have the advantage of being inexpensive, quantitative tools that can be easily applied in almost every setting, including epidemiological studies, large clinical trials, clinical research investigations, and clinical practice. [19] A significant drawback is that the physiologic state assumption in their derivation formulae is no longer obeyed in insulin-resistant nondiabetic controls, with inappropriately high glucose and inappropriately low insulin levels. [19, 20] Log transformation of both fasting insulin and glucose in the QUICKI equation, can maintain linear correlations with direct measures of IR in this clinically important state of nondiabetic individuals who are insulin resistant. [19, 20] The performance of different markers of IR has been assessed in different subpopulations and in different clinical states. HOMA-IR, at a cutoff of 2.5, had a sensitivity of >70% and a specificity of >60% for diagnosing MS in Indian adolescents. [7] HOMA-IR was also useful in diagnosing MS in Korean children. [21] FGIR has shown good predictive value for IR and MS in women with polycystic ovarian syndrome. [18, 22] In nondiabetic adult populations, QUICKI has been shown to predict impaired glucose tolerance, normal glucose tolerance, and type 2 diabetes with an AUC of 0.654, 0.686, and 0.715, respectively, in a large prospective cohort study of healthy adults, consisting of combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. [23] These values are similar to the value of 0.722 obtained from this study, for predicting MS using QUICKI. Results from the above Cohort studies showed that QUICKI ranked 3 rd , 5 th , and 5 th in AUC in predicting impaired glucose tolerance, normal glucose tolerance, and type 2 diabetes, respectively, preceded only by more direct measures of IR. [23] Findings from our study further validate reports in literature that QUICKI is among the most thoroughly evaluated and validated surrogate index for IR and can predict MS, especially in nondiabetic adult population. This study is limited by its cross-sectional design and by the lack of standardization of insulin assays between laboratories, which makes it impossible to use surrogate markers to define universal cutoff points for IR. Future directions should focus on standardization of insulin assays across laboratories to make way for the application of surrogate markers of IR in clinical practice.
Conclusion
QUICKI, a surrogate marker of IR, has shown consistency in detecting IR in an adult, nondiabetic Nigerian population, by consistently being able to distinguish between individuals, with and without MS components; correlating with the components of the syndrome; and having the largest AUC for detecting MS, compared to HOMA-IR, HOMA-B, and FGIR. At a cutoff value of 0.324, QUICKI detected MS with 90% sensitivity although with a low sensitivity of 40%.
